Instil Bio Inc. Common Stock (TIL)

About TIL

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

17

Website

instilbio.com/

Fundamentals

1-day range

$7.39$7.44

Market cap

$49.37M

P/E (trailing)

—

P/E (forward)

-0.50

EPS (trailing)

$-7.08

Dividend yield

—

Beta

1.89

Avg. volume

14.3K

Forecasts

1 analyst ratings

Instil Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TIL

  Instil Bio Inc. Common Stock

  $7.58

  ▼ 3.56%
  Market cap $49.37MP/E —
  $5.67$33.83
• ATYR

  aTyr Pharma Inc. Common Stock

  $0.5361

  ▼ 3.41%
  Market cap $49.22MP/E —
  $0.395$6.5
• EXOZ

  eXoZymes Inc. Common Stock

  $7.17

  ▼ 0.10%
  Market cap $47.57MP/E —
  $4.35$18.4
• OKYO

  OKYO Pharma Limited Ordinary Shares

  $1.67

  ▲ 7.74%
  Market cap $51.94MP/E —
  $1.34$3.2
• MGX

  Metagenomi Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $46.68MP/E —
  $1.13$3.95
• INKT

  MiNK Therapeutics Inc. Common Stock

  $11.43

  ▼ 2.16%
  Market cap $54.80MP/E —
  $8.48$16.98
• TVGN

  Tevogen Inc. Common Stock

  $6.89

  ▲ 2.07%
  Market cap $41.58MP/E —
  $3.64$49.5

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Instil Bio Q2 Adj. EPS $(0.45) Misses $(0.43) Estimate
  Benzinga · 8/13/2026

• Matcham George · June 11, 2026 · Grant

  6.5K
• Gwendolyn Binder · June 11, 2026 · Grant

  6.5K
• Gibson Neil W · June 11, 2026 · Grant

  0
• R. Kent McGaughy Jr. · June 11, 2026 · Grant

  6.5K

Institutional Ownership

March 31, 2026

Total shares held

2.23M

Total value held

$18.30M

Institutional holders

29